Guidelines for the management of adults with community-acquired pneumonia diagnosis, assessment of severity, antimicrobial therapy, and prevention

American Journal of Respiratory and Critical Care Medicine

Volumn 163, Issue 7, 2001, Pages 1730-1754

  Niederman, M S ^a   Mandell, L A ^a   Anzueto, A ^a   Bass, J B ^a   Broughton, W A ^a   Campbell, G D ^a   Dean, N ^a   File, T ^a   Fine, M J ^a   Gross, P A ^a   Martinez, F ^a   Marrie, T J ^a   Plouffe, J F ^a   Ramirez, J ^a   Sarosi, G A ^a   Torres, A ^a   Wilson, R ^a   Yu, V L ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIBIOTIC AGENT; ANTIVIRUS AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CLARITHROMYCIN; ERYTHROMYCIN; INFLUENZA VACCINE; MACROLIDE; OSELTAMIVIR; PNEUMOCOCCUS VACCINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIMANTADINE; ZANAMIVIR;

ANTIBIOTIC THERAPY; BACTERIAL PNEUMONIA; CHLAMYDOPHILA PNEUMONIAE; DISEASE SEVERITY; GRAM STAINING; HOSPITALIZATION; HUMAN; INFLUENZA; INFLUENZA VIRUS A; INFLUENZA VIRUS B; INTENSIVE CARE UNIT; LEGIONELLA; LUNG GAS EXCHANGE; MYCOPLASMA PNEUMONIAE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; RISK FACTOR; SPUTUM CULTURE; STREPTOCOCCUS PNEUMONIAE; THORAX RADIOGRAPHY;

EID: 0034959819     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.163.7.at1010     Document Type: Review

References (171)

1. Epidemiology of community-acquired respiratory tract infections in adults: Incidence, etiology, and impact
2. The cost of treating community-acquired pneumonia
3. Microbial etiology of acute pneumonia in hospitalized patients
4. New and emerging etiologies for community-acquired pneumonia with implication for therapy: A prospective multicenter study of 359 cases
5. Community-acquired pneumonia requiring hospitalization: A 5 year prospective study
6. Prospective study of the aetiology and outcome of pneumonia in the community
7. Severe community-acquired Pneumonia: Factors influencing need of intensive care treatment and prognosis
8. Severe community-acquired pneumonia. Epidemiology and prognostic factors
9. Severe community-acquired pneumonia: Etiology, prognosis, and treatment
10. Prognosis and outcomes of patients with community-acquired pneumonia: A meta-analysis
11. Etiology of community-acquired pneumonia in outpatients
12. Ambulatory patients with community-acquired pneumonia: The frequency of atypical agents and clinical course
13. Community-acquired pneumonia: Impact of immune status
14. Incidence of community-acquired pneumonia requiring hospitalization: Results of a population-based active surveillance study in Ohio
15. Etiology of community-acquired pneumonia: Impact of age, comorbidity, and severity
16. Severe community-acquired pneumonia: Risk factors and follow-up epidemiology
17. Multiple pathogens in adult patients admitted with community-acquired pneumonia: A one year prospective study of 346 consecutive patients
18. Community-acquired pneumonia in the elderly: Clinical and nutritional aspects
19. Severe community-acquired pneumonia in the elderly: Epidemiology and prognosis
20. A 5-year study of severe community-acquired pneumonia with emphasis on prognosis in patients admitted to an ICU
21. Community-acquired pneumonia
22. Current concepts: Community-acquired pneumonia
23. The aetiology of severe community-acquired pneumonia and its impact on initial, empiric, antimicrobial chemotherapy
24. Severe community-acquired pneumonia: Etiology, epidemiology, and prognosis factors
25. The aetiology, management and outcome of severe community-acquired pneumonia in the intensive care unit
26. The epidemiology of community acquired pneumonia among hospitalized adults
27. Clinical picture of Chlamydia pneumoniae requiring hospital treatment: A comparison between chlamydial and pneumococcal pneumonia
28. Chlamydia pneumoniae as a new source of infectious outbreaks in nursing homes
29. Etiology of community acquired pneumonia in Valencia, Spain: A multicenter prospective study
30. Incidence of community-acquired pneumonia and Chlamydia pneumoniae infection: A prospective multicenter study
31. Chlamydia pneumoniae as a cause of community-acquired pneumonia in hospitalized patients in Berlin
32. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain
33. Bacteremia with Streptococcus pneumoniae: Implications for therapy and prevention
34. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial Surveillance Program
35. Antibiotic resistance among clinical isolates of Haemophilus influenzae in the United States in 1994 and 1995 and detection of beta-lactamase-positive strains resistant to amoxicillin-clavulanate: Results of a national multicenter surveillance study
36. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997
37. Pneumonia acquired in the community through drug-resistant Streptococcus pneumoniae
38. Antimicrobial-drug resistance
39. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease
40. Recommendations on the management of chronic bronchitis: A practical guide for Canadian physicians
41. Treatment cost of acute exacerbations of chronic bronchitis
42. Bacterial infection in chronic obstructive pulmonary disease
43. Guidelines for the initial management of adults with community-acquired pneumonia: Diagnosis, assessment of severity, and initial antimicrobial therapy
44. Practice guidelines for the management of community-acquired pneumonia in adults
45. Canadian guidelines for the initial management of community-acquired pneumonia: An evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society
46. Re-evaluation of pneumonia requiring admission to an intensive care unit: A prospective study
47. Severe community-acquired pneumonia: Assessment of severity criteria
48. Accuracy of Gram's stain in identifying pneumococci in sputum
49. Diagnostic testing for community-acquired pneumonia
50. Efficacy of clarithromycin against Mycoplasma pneumoniae
51. Pathogenesis of airway colonization: Lessons learned from studies of bacterial adherence
52. Is Streptococcus pneumoniae the leading cause of pneumonia of unknown etiology? A microbiologic study of lung aspirates in consecutive patients with community-acquired pneumonia
53. Implication for macrolide treatment in community-acquired pneumonia
54. Medical outcomes and antimicrobial costs with the use of the American Thoracic Society guidelines for outpatients with community-acquired pneumonia
55. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia
56. Validation of the therapeutic recommendations of the American Thoracic Society (ATS) guidelines for community acquired pneumonia in hospitalized patients
57. Effect of macrolides as part of initial empiric therapy on length of stay in patients hospitalized with community-acquired pneumonia
58. Multivariate analysis of risk factors for infection due to penicillin-resistant and multidrug-resistant Streptococcus pneumoniae: A multicenter study
59. Management of community-acquired pneumonia in the era of pneumococcal resistance: A report from the drug-resistant Streptococcus pneumoniae Therapeutic Working Group
60. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States
61. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada
62. Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia
63. Penicillin resistance and other predictors of mortality in pneumococcal bacteremia in a population with high human immunodeficiency virus seroprevalence
64. The drug-resistant pneumococcus: Clinical relevance, therapy, and prevention
65. Drug-resistant Streptococcus pneumoniae
66. Predictive factors for invasive disease due to penicillin-resistant Streptococcus pneumoniae: A population-based study
67. Community-acquired pneumonia in old age: A prospective study of 91 patients admitted from home
68. Etiology of severe pneumonia in the very elderly
69. Tuberculosis as an epidemic and nosocomial infection among the elderly in nursing homes
70. Epidemiology of acute respiratory illness during an influenza outbreak in a nursing home: A prospective study
71. Influence of age on symptoms at presentation in patients with community-acquired pneumonia
72. A prediction rule to identify low-risk patients with community-acquired pneumonia
73. Bacterial pneumonia in hospitalized patients with HIV infection: The pulmonary complications, ICU support, and prognostic factors of hospitalized patients with HIV study
74. Risk factors for Staphylococcus aureus nosocomial pneumonia in critically ill patients
75. Raised respiratory rate in elderly patients: A valuable physical sign
76. High resolution computed tomography for the diagnosis of community-acquired pneumonia
77. Quality of care, process, and outcomes in elderly patients with pneumonia
78. Do pulmonary radiographic findings at presentation predict mortality in patients with community-acquired pneumonia?
79. Predicting death in patients hospitalized for community-acquired pneumonia
80. Community-acquired pneumonia: Aetiology and usefulness of severity criteria on admission
81. Diagnosis of Legionella pneumophila, Mycoplasma pneumoniae, or Chlamydia pneumoniae lower respiratory infection using the polymerase chain reaction on a single throat swab specimen
82. Reevaluation of the definition of Legionnaire's disease: Use of the urinary antigen assay
83. Bacterial pneumonia associated with HIV-1 infection
84. Microscopic and bacteriologic analysis of expectorated sputum
85. Invasive techniques for the diagnosis of lower respiratory tract infections
86. An acute infection of the respiratory tract with atypical pneumonia
87. Growth on artificial medium of an agent associated with atypical pneumonia and its identification as a PPLO
88. Bacteremic Hemophilus influenzae pneumonia in adults: A report of 24 cases and a review of the literature
89. A new Chlamydia psittaci strain, TWAR, isolated in acute respiratory tract infections
90. Legionnaire's disease: Report of 65 nosocomially acquired cases and a review of the literature
91. Comparative clinical laboratory features on legionella with pneumococcal and mycoplasma pneumonias
92. Prediction of microbial aetiology at admission to hospital for pneumonia from the presenting clinical features
93. A prospective study of community-acquired pneumonia in Hong Kong
94. Comparative radiographic features of community-acquired Legionnaires disease, pneumococcal pneumonia, mycoplasma pneumonia, and psittacosis
95. Bacterial or nonbacterial pneumonia: Accuracy of radiographic diagnosis
96. A hospital study of community-acquired pneumonia in the elderly
97. A comparison of nursing home-acquired pneumonia patients with patients with community-acquired pneumonia and nursing home patients without pneumonia
98. Hospitalized pneumonia cases in Pennsylvania: A comparison of outcomes, treatment patterns and costs across urban and rural areas
99. Variation in hospital admissions among small areas: A comparison of Maine and Michigan
100. The hospital management of community-acquired pneumonia
101. A controlled trial of a critical pathway for treatment of community-acquired pneumonia
102. Aetiology, outcome and prognostic factors in community-acquired pneumonia requiring hospitalization
103. Predicting the need for hospitalization of ambulatory patients with pneumonia
104. Use of prognostic scoring and outcome assessment tools in the admission decision for community-acquired pneumonia
105. Safely increasing the proportion of patients with community-acquired pneumonia treated as outpatients: An interventional trial
106. Preference for home vs. hospital care among low-risk patients with community-acquired pneumonia
107. Clinical efficacy of intravenous followed by oral azithromycin monotherapy in hospitalized patients with community-acquired pneumonia
108. Azithromycin vs. cefuroxime plus erythromycin for empirical treatment of community-acquired pneumonia in hospitalized patients: A prospective, randomized, multicenter trial
109. Implementation of admission decision support for community-acquired pneumonia
110. Impact of a practice guideline for community-acquired pneumonia in an outpatient setting
111. Treatment of respiratory infections with quinolones
112. Parenteral followed by oral ofloxacin for nosocomial pneumonia and community-acquired pneumonia requiring hospitalization
113. Oral ofloxacin for the treatment of acute bacterial pneumonia: Use of a nontraditional protocol to compare experimental therapy with "usual care" in a multicenter clinical trial
114. Initial microbiologic studies did not affect outcome in adults hospitalized with community-acquired pneumonia
115. Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia
116. A double-blind, randomized, multicenter, global study in hospitalized community-acquired pneumonia (CAP) comparing trovafloxacin with ceftriaxone + erythromycin
117. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime in treatment of adults with community acquired pneumonia
118. Treating community-acquired pneumonia with once-daily gatifloxacin vs. once-daily levofloxacin
119. Three levofloxacin treatment failures of pneumococcal respiratory tract isolates
120. Pneumococcal macrolide resistance: Myth or reality?
121. Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin
122. Bacteremic pneumonia due to multidrug-resistant pneumococci in 3 patients treated unsuccessfully with azithromycin and successfully with levofloxacin
123. Fatal pneumococcal pneumonia attributed to macrolide resistance and azithomycin monotherapy
124. Antibiotics for pneumonia therapy
125. Efficacy of a three day course of azithromycin in moderately severe community-acquired pneumonia
126. Doxycycline is a cost-effective therapy for hospitalized patients with community-acquired pneumonia
127. Treatment of severe pneumonia in hospitalized patients: Results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin
128. A prospective randomized study of inpatient IV antibiotics for community-acquired pneumonia
129. Comparison of azithromycin and erythromycin in the treatment of atypical pneumonias
130. Azithromycin versus cefaclor in the treatment of acute bacterial pneumonia
131. Pneumococcal bacteremia in adults: Age-dependent differences in presentation and in outcome
132. Radiographic resolution of community-aquired pneumonia
133. Clinical diagnosis of pneumococcal, adenoviral, mycoplasmal and mixed pneumonias in young men
134. Time to clinical stability in patients hospitalized with community-acquired pneumonia: Implications for practice guidelines
135. The radiologic resolution of Streptococcus pneumoniae pneumonia
136. Switch therapy in adult patients with pneumonia
137. Early switch from intravenous to oral antibiotics and early hospital discharge: A prospective observational study of 200 consecutive patients with community-acquired pneumonia
138. Early switch from intravenous to oral antibiotics in hospitalized patients with bacteremic Streptococcus pneumoniae community-acquired pneumonia
139. Determinants of non-compliance with short term antibiotic regimens
140. Evaluation of a pneumonia practice guideline in an interventional trial
141. The clinical benefit of in-hospital observation in "low risk." pneumonia patients after conversion from parenteral to oral antimicrobial therapy
142. Prospective audit of the value of fibreoptic bronchoscopy in adults admitted with community-acquired pneumonia
143. Utility of fiberoptic bronchoscopy in nonresolving pneumonia
144. Nonresolving pneumonia in steroid-treated patients with obstructive lung disease
145. Bacteremic pneumococcal pneumonia: A continuously evolving disease
146. Diagnostic accuracy of protected specimen brush and bronchoalveolar lavage in nosocomial pneumonia: Impact of previous antimicrobial treatments
147. Diagnostic fiberoptic bronchoscopy and protected brush culture in patients with community-acquired pneumonia
148. The value of open lung biopsy in immunocompetent patients with community-acquired pneumonia requiring hospitalization
149. Prevention of pneumococcal disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
150. A controlled evaluation of the protective efficacy of pneumococcal vaccine for patients at high risk of serious pneumococcal infections
151. Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people
152. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine
153. Pneumococcal polysaccharide vaccine efficacy: An evaluation of current recommendations
154. Efficacy of pneumococcal vaccine in high risk patients: Results of a veterans administration cooperative study
155. Immunization of adolescents: Recommendations of the Advisory Committee on Immunization Practices (ACIP), the American Academy of Pediatrics, the American Academy of Family Physicians, and the American Medical Association
156. Improving the use of pneumococcal vaccine through a strategy of hospital-based immunization: A review of its rationale and implications
157. Hospital-based pneumococcal immunization: Epidemiologic rationale from the Shenandoah study
158. Policy statement and technical report: Recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prenevar), pneumococcal polysaccharide vaccine, and antibiotic-prophylaxis
159. Emerging infections: Pandemic influenza
160. The efficacy of influenza vaccine in elderly persons: A meta-analysis and review of the literature
161. Clinical effectiveness of influenza vaccination in Manitoba
162. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community
163. Frequency of adverse reactions to influenza vaccine in the elderly: A randomized, placebo-controlled trial
164. Guillain-Barré syndrome in the United States, 1979-1980 and 1980-1981: Lack of an association with influenza vaccination
165. Prevention and control of influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
166. Prevention and treatment of influenza in immunocompromised patients
167. Zanamivir in the prevention of influenza among healthy adults: A randomized controlled trial
168. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza
169. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections
170. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: A randomized controlled trial